Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(raltegravir)
1,791 results
  • Laboratory surrogate markers of residual HIV replication among distinct groups of individuals under antiretroviral therapy. [Journal Article]
  • PlosPLoS One 2019; 14(6):e0217502
  • Giron LB, Tenore SB, … Diaz RS
  • CONCLUSIONS: Residual HIV replication has been inferred among individuals under suppressive ART according to episomal DNA detection. Residual replication may decrease with longer periods of suppressive ART and higher levels of CD4+ and CD8+ T cells. The relationship between episomal DNA and total DNA suggests there is a replenishment of the proviral reservoir with impacts on HIV persistence. Lower antibody and LPS levels among patients with initial PI-r ART suggest these regimens may more effectively suppress HIV and have a higher capacity to decrease the HIV antigenic component.
  • Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey. [Journal Article]
  • RERev Esp Quimioter 2019; 32(3):263-267
  • Cecchini DM, Castillo S, … Cassetti I
  • CONCLUSIONS: Integrase resistance test was prescribed almost exclusively in heavily pretrated raltegravir-exposed patients. The three main mutational pathways were described, with a predominance of N155H. Despite almost null susceptibility and extensive cross resistance was shown among raltegravir and elvitegravir, dolutegravir remains active in the majority of patients.
New Search Next